Capstone Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Capstone Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$282K	Buy	+15,681	New	+$297K	﹤0.01%	1482
2025 Q4	–	Sell	-30,000	Closed	-$578K	–	2024
2025 Q3	$578K	Buy	+30,000	New	+$535K	﹤0.01%	1288
2025 Q2	–	Sell	-19,850	Closed	-$1.27M	–	1725
2025 Q1	$1.27M	Buy	+19,850	New	+$2.09M	﹤0.01%	817
2014 Q3	–	Sell	-31,100	Closed	-$702K	–	496
2014 Q2	$926K	Buy	+31,100	New	+$983K	0.01%	319
2013 Q3	–	Sell	-30,511	Closed	-$1.18M	–	549
2013 Q2	$1.16M	Buy	+30,511	New	+$1.09M	0.01%	335

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Capstone Investment Advisors's SRPT Position: Q2 2026 in Review

Capstone Investment Advisors opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 15,681 shares worth $282K. The stake represents ﹤0.01% of the portfolio and ranks #1482 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in SRPT as recently as Q3 2025.

Capstone Investment Advisors first reported a position in SRPT in Q2 2013 and has held it in 5 quarters since. The position peaked at $1.27M in Q1 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Capstone Investment Advisors held 15,681 shares of Sarepta Therapeutics worth $282K as of Q2 2026.
Sarepta Therapeutics was a new Capstone Investment Advisors position in Q2 2026.
Sarepta Therapeutics made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1482 holding.
Capstone Investment Advisors first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 5 quarters since.
Capstone Investment Advisors's Sarepta Therapeutics position peaked at $1.27M in Q1 2025.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.